The deal is largely locked in with >44% of votes already committed. The key variable for XOMAP holders is the pre-closing redemption of the perpetual preferred at par plus accrued dividends, which caps the upside at the redemption price. Common shareholders should expect $39.00 per share at close; the CVR is a free option on the Janssen litigation but may pay nothing. Trade the spread to close (currently ~Q3 2026) with limited risk of deal break given the vote commitments.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Jun 11 $25.51entry
- T+1 · 5mo ago −0.18%α −0.72% · $25.47
- T+5 · 5mo ago −0.35%α −0.79% · $25.42
- T+20 · 4mo ago −2.07%α −3.96% · $24.98
- T+60 · due 2mo ago Pending
Price Chart
How similar events traded
Executive Summary
XOMA Royalty filed its definitive proxy statement on Schedule 14A, setting a special stockholder meeting for July 13, 2026 to approve the all-cash acquisition by Ligand Pharmaceuticals. Stockholders will receive $39.00 per share plus one contingent value right (CVR) tied to the Janssen litigation, with the board and holders of >44% of voting shares already committed to vote in favor. The merger is expected to close in Q3 2026, after which XOMA's common stock (XOMA) and preferred stock (XOMAP, XOMAO) will be delisted and the perpetual preferred shares redeemed.
Key Financial Metrics
Key Facts
- Special meeting to vote on merger set for July 13, 2026; record date June 5, 2026.
- XOMA shareholders receive $39.00 per share in cash plus one CVR per share tied to the Janssen litigation.
- Ligand Pharmaceuticals is acquiring XOMA in a transaction valued at ~$739M aggregate.
- Board unanimously recommends FOR all proposals and >44% of voting power pre-committed via support agreements (BVF holds 43.0%, insiders 1.3%).
- Perpetual preferred stock (Series A XOMAP and Series B XOMAO) to be redeemed pre-closing with all accrued dividends paid.
- CVRs are non-transferable, not listed, highly contingent on the outcome of the Janssen litigation, and may have zero value.
- Merger requires approval of a majority of outstanding common shares, so abstentions/broker non-votes count as 'against'.
- Dissenters' rights available under Nevada law for common shareholders who do not vote in favor and comply with statutory procedures.
- Leerink Partners rendered fairness opinion that $39.00 cash consideration is fair from a financial point of view.
- Termination fee of $40 million payable by XOMA in certain circumstances.
- Expected close in Q3 2026; Hart-Scott-Rodino waiting period is a closing condition.
Financial Impact
Aggregate deal value ~$739M based on 17.7M shares × $39.00. Shareholders also receive CVRs with uncertain value tied to the Janssen patent litigation.
Risk Factors
- CVRs may have zero value if the Janssen litigation is unsuccessful or takes years to resolve.
- Failure to obtain regulatory approvals or stockholder approval could block or delay the merger.
- Merger agreement limits XOMA's ability to solicit alternative proposals; $40M termination fee may deter competing bids.
- If the merger fails, XOMA's stock may trade down meaningfully with lost premium and the cost of proxy/transaction expenses.
- Preferred shareholders who do not tender will have their shares forcibly redeemed; timing of redemption could affect dividend accrual.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFM14A Filing (Primary) | 0001193125-26-266069 |
| Document: d137792ddefm14a.htm | 0001193125-26-266069 |
Track record
6 reports on XOMAP
3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +0.47% at T+20 after the May 26, 2026 report. 3 of 3 went positive at some point.
Filters
- Jun 10, 202622w ago DEFM14A Bullish 8/10 Viewing Entry $25.51 to $24.98 ▼ −2.07% −3.96% vs SPY
- May 26, 202624w ago 425 Bullish 7/10 Entry $25.36 to $25.48 ▲ +0.47% +2.42% vs SPY
- May 18, 202626w ago DEFA14A Neutral 4/10 Entry $25.38 to $25.40 ▲ +0.08% −1.50% vs SPY
- Apr 27, 202629w ago DEFA14A Bullish 8/10 Entry $25.25 to $25.36 ▲ +0.44% −4.52% vs SPY
- Apr 27, 202629w ago 8-K Bullish 8/10 Entry $25.25 to $25.36 ▲ +0.44% −4.52% vs SPY
- Mar 30, 202633w ago DEFA14A Neutral 3/10 Entry $25.74 to $25.62 ▼ −0.47% −9.89% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers